Confirming previous data obtained on smaller cohorts [10, 16], our findings showed that gliomas patients harboring an IDH1 mutated tumor present an improved outcome, compared to patients with an IDH1 normal tumor. This evidence concerns the gene IDH1 and central nervous system cancer.